The Evils of Big Pharma: 1st their “Anti-Depressants” Command Patients to Commit Suicide, Now, Big Pharma Gets to Give you the Same Pills to Get Over your Grief!

December 28, 2012


CAN MEDICAL RESEARCH BE TRUSTED?A Washington Post investigation finds pharmaceutical companies influence the research that determines drug prescriptions for millions of Americans.

Antidepressants to treat grief? Psychiatry panelists with ties to drug industry say yes

File photo/AP – When should the bereaved be medicated? For years, the official handbook of psychiatry advised against diagnosing major depression when the distress is “better accounted for by bereavement.” Such grief, experts said, was better left to nature. But that may be changing.

By Published: December 26

It was a simple experiment in healing the bereaved: Twenty-two patients who had recently lost a spouse were given a widely used antidepressant.The drug, marketed as Wellbutrin, improved “major depressive symptoms occurring shortly after the loss of a loved one,” the report in the Journal of Clinical Psychiatry concluded.

Pharmaceutical company ties with depression panel members.

Click Here to View Full Graphic Story

Pharmaceutical company ties with depression panel members.

When, though, should the bereaved be medicated? For years, the official handbook of psychiatry, issued by the American Psychiatric Association, advised against diagnosing major depression when the distress is “better accounted for by bereavement.” Such grief, experts said, was better left to nature.But that may be changing.

In what some prominent critics have called a bonanza for the drug companies, the American Psychiatric Association this month voted to drop the old warning against diagnosing depression in the bereaved, opening the way for more of them to be diagnosed with major depression — and thus, treated with antidepressants.

The change in the handbook, which could have significant financial implications for the $10 billion U.S. antidepressant market, was developed in large part by people affiliated with the pharmaceutical industry, an examination of financial disclosures shows.

The association itself depends in part on industry funding, and the majority of experts on the committee that drafted the new diagnostic guideline have either received research grants from the drug companies, held stock in them, or served them as speakers or consultants.

Drug companies have shown an interest in treating patients who have recently lost a loved one, having sponsored and published the results of at least three trials in which the bereaved were treated with antidepressants, including the Wellbutrin study.

The financial ties between the creators of the APA handbook and the industry far exceed limits recommended in 2009 by the Institute of Medicine, a branch of the National Academy of Sciences.

The IOM limits reflect the fear that patient health could be compromised when diagnostic and treatment guidelines, which are widely used by doctors, are written largely by industry-hired experts and issued by medical societies that depend on industry funding.

While no evidence has come to light showing that committee members broadened the diagnosis to aid the drug companies, the process of developing the handbook was fraught with financial links to the industry:

■ Eight of 11 members of the APA committee that spearheaded the change reported financial connections to pharmaceutical companies — either receiving speaking fees, consultant pay, research grants or holding stock, according to the disclosures filed with the association. Six of the 11 panelists reported financial ties during the time that the committee met, and two more reported financial ties in the five years leading up to the committee assignment, according to APA records.

■ A key adviser to the committee — he wrote the scientific justification for the change — was the lead author of the 2001 study on Wellbutrin, sponsored by GlaxoWellcome, showing that its antidepressant Wellbutrin could be used to treat bereavement.

12/27/2012 6:16 PM EST
Drug companies, of course, find it inconvenient that its a well-known fact that antidepressants do cause people to commit suicide. They are not in the drug business, primarily, to help people; in the final anaylsis, they’re in it for profits above anything else. As evidence for this assertion, they don’t produce medicines for rare disorders. Government must subsidize costs to produce so-called orphaned drugs for rare diseases.

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: